

TABULÆ ANATOMICÆ

CLARISSIMI VIRI

BARTHOLOMÆI

EUSTACHII

Quas è tenebris tandem vindicatas

ET

CLEMENTIS PAPÆ XI.

Munificentia dono acceptas,

PRÆFATIONE, AC NOTIS ILLUSTRAVIT

JOH. MARIA LANCIUSIUS

ARCHIATER PONTIFICIUS.

EDITIO ROMANA ALTERA.



ROMÆ MDCCXXVIII.

Sumptibus Laurentii, & Thomæ Pagliarini Bibliop. sub signo Palladis.

Ex Typographiâ Rochi Bernabè. X Superiorem perrefigit.

TAB. ANATOM.

3

TABULA II.

*Novas exhibet eorundem renum, incumbantium glandularum,
& vasorum figuras.*

MR & GR

FIGURA PRIMA.



In prima Figura renes, magnitudine parum, aut nihil differunt; & dexter nonnihil est humilior; sinister parum elatior.

Glandulæ renibus incumbentes; depressæ, & oblongæ, ac si essent duæ placentulæ, 3. 12. & 2. 14.

Vena cava, 2. 16. & 16. 16.

Arteria magna, 4. 18. 14. 18.

Vena à cava juxta hepar originem ducens; partim dextræ glandulæ reni incumbentis corpus perforat; partim superficiem ejusdem perreptat, 2. 13.

Venula in eandem glandulam inserta; originem trahens ab emulgente vena juxta cavam, 5. 14.


Adrenals

- The first description of adrenals origins from the year 1563. It is an illustration done by Bartolomeo Eustachio "Glandulae Renibus Incumentes" (published in 1714).




- In 1849 Thomas Addison published the description of lethal effects of adrenal failure, which began the modern research of adrenal cortex physiology.

- Till the half of XX century most experiments on adrenal cortex focused on carbohydrates and glucocorticoids.


- Glucocorticoids were regarded as compounds of both glucocorticoid and mineralocorticoid activities.



Aldosterone and cortisol synthesis



Glucocorticoid



Mineralocorticoid

Aldosterone is at 1000 fold lower concentrations than cortisol

Average 8 AM plasma concentration and secretion rates of adrenocortical steroids in adult humans


	<i>Plasma concentration ($\mu\text{g/dl}$)</i>	<i>Secretion rate mg</i>
Cortisol	13	15
Corticosterone	1	3
11-Deoxycortisol	0.16	0.40
Deoxycorticosterone	0.07	0.20
Aldosterone	0.009	0.15
18-OH Corticosterone	0.009	0.10
Dehydroepiandrosterone sulfate	115	15

Aldosterone in the blood

- Aldosterone was isolated in 1953 (21 mg aldosterone from 500 kg of bovine adrenals), a year later its structure was characterized.
- Most aldosterone is synthesized in adrenal cortex, in zona glomerulosa.
- Aldosterone is also produced in other tissues, e.g. in the heart, blood vessels and brain.
- In the blood only ~50% aldosterone is bound to transporting proteins (mostly albumins) (cortisol: 90-95% is bound to proteins).
- Half-life time in the blood for aldosterone is ~20 minutes (cortisol: ~70 minutes).
- 90% aldosterone is removed after single passing through the liver (here aldosterone is bound to glucoronide acid, which increases its water solubility and facilitates its removal with the urine; similarly in the case of cortisol)

Overproduction of aldosterone – Conn's disease

(described in 1955 by J.W. Conn; it fact it was first described by M. Lityński in 1953, but he published it in the polish journal)




Michal Litynski

Cause:


- Mostly tumors developing from adrenal cortex cells (adrenal adenoma), usually at the age 30-50. It can be also caused by adrenal hyperplasia.

Symptoms:

- Strong hypertension,
- Hypokalemia,
- Alcalosis,
- Light hypernatremia,
- Polyuria,
- Tiredness,
- Weakness of muscles.



Schematic structure of the human MR and GR




Variable proportions of aldosterone (MR) and glucocorticoid (GR) binding sites among human tissues

Cell Type	MR	GR	MR/GR
Renal collecting duct	10,000/cell	20,000/cell	1/2
Colonic epithelium	7,000/cell	21,000/cell	1/3
Brain hippocampus	100 fmol/mg protein	100 fmol/mg protein	1/1
Arterial smooth muscle cells	1,000/cell	30,000/cell	1/30
Cardiac myocytes	10 fmol/mg protein	300 fmol/mg protein	1/30

Mineralocorticosteroid receptor (MR)

- MR was cloned in 1987.
- The MR gene consists of 9 exons. It has two exons 1 (exon 1 α and exon 1 β), each with an alternative promoter. However, the finally translated MR protein is the same.






Mineralocorticosteroid receptor (MR)

- Major ligands of MR:

* **aldosterone** – major MR ligand exerting physiological effects.

* **cortisol** – has higher affinity to MR than aldosterone, but in major target tissues for aldosterone (e.g. in kidneys) enzyme **11 β -hydroxysteroid dehydrogenase (11 β -HSD2)** metabolizes cortisol to cortisone, which does not bind to MR. In the case of defect or deficiency of this enzyme cortisol starts to act as a mineralocorticoid.








- Regulation of ligand selectivity for MR does not occur at the receptor level, but at the level of **11β-HSD2 activity** (epithelium in kidney tubules, bladder, gastrointestinal tract, saliva glands, sweat glands, vascular smooth muscle cells and endothelium) only **aldosterone** may activate MR. In the **brain and miocytes**, which do not express 11β-HSD2 – the major **MR activator is cortisol**.

Activity of aldosterone


- Major task for aldosterone is to save water and sodium as well as maintain the appropriate volume of extracellular fluids (volume of primary urine reaches ~170 L/day and ~1.5 kg of salt...).
- Major target site for aldosterone are **kidneys and their distal and collecting tubules**, where aldosterone increases the resorption of Na^+ , decreasing removal of Na^+ with urine. On the other hand, it increases removal of K^+ and H^+ , because Na^+ ions are exchanged to K^+ and H^+ .
- Aldosterone increases the volume of extracellular fluids and increases blood pressure.
- Aldosterone decreases the loss of sodium with sweat and saliva.

E.g. if in response to training someone starts to sweat, the first perspirate contains a lot of sodium. However, decrease in volume of extracellular fluid leads to increased synthesis of aldosterone and decreased loss of sodium. The sweat becomes in practice sodium-free (thus, drinking the "balanced" or "isotonic drinks" is usually useless).






Sodium absorption by the renal tubular system



Schematic depicting the sodium-chloride cotransporter (NCC), the potassium channel (ROMK), the sodium channel (ENaC)

Coffman, Nat Genetics 2006



Regulation of sodium absorption




- Aldosterone binds to the MR;
- Activation of MR leads to increased expression of Sgk-1, which phosphorylates Nedd4-2.
- Phosphorylated Nedd4-2 no longer interacts with internalised the ENaC, leading to **increased expression of ENaC** at the apical membrane.
- Activation of MR also leads to **increased expression of Na⁺/K⁺-ATPase**, thus causing a net increase in sodium uptake from the renal filtrate.

Regulation of aldosterone action


- Concentration of aldosterone decreases in response to increase in the volume of extracellular fluid.

I. Hypervolemia is checked in atrium of the heart, which releases **atrial natriuretic peptide (ANP)** in response to atrial dystension. ANP binds to the receptors in zona glomerulosa and decreases the synthesis of aldosterone.


II. Hypervolemia is also checked in juxtaglomerular apparatus (JGA) in the kidney. In response to hypervolemia the production of **renin** decreases leading to reduced synthesis of **angiotensin-II (AngII)** and decreased synthesis of aldosterone. Even small changes in AngII lead to strong responses in the aldosterone level.



Renin-Angiotensin-Aldosterone Mechanism



Hypertension



* **Silent Killer** – harmful complications,

* causes dizziness, headache, and visual difficulties,

* Leading risk factor in cardiovascular diseases

* Number one reason for drug prescription.

* 25% of population; among them: ~5% ..!


Normal: 120/80 +/- 10/5

Mild + 20, Moderate +40, Severe +80; Malignant - > 210/120


Consequences of Hypertension:

Cardiovascular system:

Hypertensive cardiomyopathy




Atherosclerosis




Consequences of Hypertension:

Brain:

Stroke (infarction)




Haemorrhage



Consequences of Hypertension:


Eye:

Hypertensive
retinopathy




Aldosterone in the heart

- High concentrations of aldosterone, especially combined with a high-salt diet leads to **cardiac fibrosis**.
- This effect is inhibited by **spironolactone** lub **eplerenone** – MR antagonists.
- Aldosterone in the heart may lead to necrosis of cardiomyocytes and activation of macrophages.
- Fibrosis is possible a secondary repair process.
- The primary cause of injury is inflammation and necrosis of cardiomyocytes.




Myocardial Histopathology in Aldosterone/NaCl-treated Hypertensive Rats



Aldo/NaCl


Inflammatory infiltrate




Aldo/NaCl + eplerenone

Healthy myocardium

Rat heart



COX-2



MCP-1

RALES trial

(1600 patients
with severe heart failure)

Spirolactone competitively antagonizes aldosterone binding but may cause endocrine disturbances as a result of its nonselective binding affinity for progesterone and androgen receptors (used in male-to-female transsexual people).





FIG. 3. Survival curves among patients treated with placebo or spironolactone. Risk of death was 30% lower in the spironolactone-treated group in the RALES trial ($P < 0.001$). [Reproduced with permission from B. Pitt *et al.*: *N Engl J Med* 341:709, 1999 (76).]

Cortisol


- corticosteroids are not stored, but are always synthesised de novo from cholesterol
- level of circulating corticosteroids is the highest in the morning,
- circulating corticosteroids are associated with transcortine (cortisol binding globulin, CBG, α 2-globulin glycoprotein, 75-80%) i albumins (15%). 5-10% is free.



- On cells there are **membrane receptors for transcortine**. Binding the ligands (complex transcortine-cortisol) leads to elevation of cAMP and **mediates non-genomic effects of cortisol**.

Hypoactivity of adrenal cortex – Addison disease

- Fatigue, no tolerancy for even small stress,
- Fever,
- Insuline oversensitivity,
- Fasting hypoglycemia,
- No apetite,
- Nusea,
- Loss of weigh,
- Anemia,
- Weakness,
- Low blood pressure,
- Consuming large amounts of salt,
- Increased number of lymphocytes and eosinophils, decreased neutrophils,
- Hair loss,
- Increased pigmentation of skin and mucosa (because of increased secretion of ACTH and activation of propiomelanocortine).



Hyperactivity of adrenal cortex – Cushing syndrome

Causes:

- treatment with pharmacological doses of corticosteroids
- overproduction of ACTH (e.g. pineal cancer, hyperplasia of pineal gland)

Symptoms:

- abdominal obesity with bull hump and round face,
- osteoporosis,
- thin skin with red striae,
- muscle weakness and atrophy,
- bruises after even weak trauma,
- hair loss,
- impaired wound healing,
- weak response to infections,
- hyperglycemia and increased neoglucogenesis,
- aggressiveness and depression
- high blood pressure




Cortisol activity


- ↑ glukoneogenesis, ↓ insulin sensitivity; results in hyperglycemia
- ↑ lipolysis (mostly in the extremities), ↓ lipogenesis, fat redistribution – abdominal obesity (belly, corpus, face)
- ↓ production of collagen type I, ↓ maturation of osteoblast progenitors, ↓ calcium absorption in intestine; too high level of cortisol leads to osteoporosis.
- in cardiovascular system it contributes to regulation of normal blood pressure: ↑ heart beating, ↑ response of arterioles to catecholamines which increases blood pressure, ↓ production of vasodilating prostaglandin, ↓ endothelium permeability, which protects against edema in inflamed tissues.
- in the kidneys it acts in a opposite way to aldosterone: ↑ removal of water from organism, ↓ secretion of vasopresine (an antidiuretic hormone) from hypothalamus.


Glucocorticoid receptors

- GR is commonly expressed in the cells in number of 3 000 - 30 000 molecules per cell.
- GR without ligands are located in the cytoplasm, where are bound with Hsp90
- GR is active as a homodimer, which recognize the palindromic sequence TGTTCT
- GR exists in two splicing forms:
 - * α (777 aminoacids)
 - * β (742 aminoacids, lack of C-terminal fragment)
- Isoform β cannot bind ligands, although it may bind to DNA. Possibly it may inhibit activity of glucocorticoids.



Potential Mechanism for Action of the Glucocorticoid Receptor (GR) β isoform






Cortisol and immunological system

- in pharmacological doses is used as **an antiinflammatory compound**, which prevents also transplant rejection
- induces lipocortine, which inhibits phospholipase A2 producing arachidonic acid, a precursor of prostaglandins; thus it **inhibits prostaglandin synthesis**
- stabilizes lysosomal membranes, decreasing local release of proteolytic enzymes and hyaluronidase in the site of inflammation
- **decreases proliferation of mastocytes** and thereby inhibits production of histamine in the inflamed tissue (but does not inhibit release of histamine from existing mastocytes)
- **decreases leukocytic infiltrations**, decreasing the synthesis of chemoattractants, and decreasing the permeability of endothelium
- cortisol **inhibits the expression of e.g. IL-1, IL-6, IFN γ , TNF α** (but may upregulate their receptors on the target cells)

Cellular effects of glucocorticosteroids



Corticosteroids and gene transcription

Increased transcription

Annexin-1 (lipocortin-1, phospholipase A₂ inhibitor)
β₂-adrenergic receptor
Secretory leukocyte inhibitory protein
Clara cell protein (CC10, phospholipase A₂ inhibitor)
IL-1 receptor antagonist
IL-1R2 (decoy receptor)
IκBα (inhibitor of NF-κB)
IL-10 (indirectly)

Decreased transcription

Cytokines

IL-1, IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-11, IL-12, IL-13, IL-16, IL-17,
IL-18, TNF-α, GM-CSF, SCF

Chemokines

IL-8, RANTES, MIP-1α, MCP-1, MCP-3, MCP-4, eotaxin

Adhesion molecules

ICAM-1, VCAM-1, E-selectin

Inflammatory enzymes

Inducible nitric oxide synthase
Inducible cyclooxygenase
Cytoplasmic phospholipase A₂

Inflammatory receptors

Tachykinin NK₁-receptors, NK₂-receptors
Bradykinin B₂-receptors

Peptides


Endothelin-1

Healthy synovial joint


- The synovial joint is composed of two adjacent bony ends each covered with a layer of cartilage, separated by a joint space and surrounded by the synovial membrane and joint capsule.

- The synovial membrane is normally $<100\ \mu\text{m}$ thick and the synovial lining consists of a thin (1–3 cells) layer of synoviocytes (macrophage derived and fibroblast derived);

- Only a few, if any, mononuclear cells are interspersed in the sublining connective tissue layer, which has considerable vascularity. The synovial membrane covers all intra-articular structures except for cartilage and small areas of exposed bone and inserts near the cartilage–bone junction.



Rheumatoid arthritis



- Rheumatoid arthritis (RA) is characterized by an inflammatory response of the synovial membrane conveyed by a transendothelial influx and/or local activation of T cells, B cells, plasma cells, dendritic cells, macrophages, mast cells, as well as by new vessel formation.

The lining layer becomes hyperplastic (a thickness of >20 cells) and the synovial membrane expands and forms villi.

- The hallmark of RA is bone destruction. The destructive cellular element is the osteoclast; destruction mostly starts at the cartilage–bone–synovial membrane junction. Bone repair by osteoblasts usually does not occur in active RA.

- The neutrophils' enzymes, together with enzymes secreted by synoviocytes and chondrocytes, lead to cartilage degradation.

Rheumatoid arthritis

healthy



arthritic



Rheumatoid Arthritis: Key Features

- **Symptoms >6 weeks' duration**
 - Often lasts the remainder of the patient's life
- **Inflammatory synovitis**
 - Palpable synovial swelling
 - Morning stiffness >1 hour, fatigue
- **Symmetrical and polyarticular (>3 joints)**




Rheumatoid Arthritis


- Affects approximately 1% of the adult U.S. population
- Incidence increases with age
- Occurs 2-4 times more often in women
- Shortens lifespan by 3-18 years (average of 10 years)



Role of Tumor Necrosis Factor in Rheumatoid Arthritis



Joint destruction



Asthma

- Inflammatory reaction and reversible constriction of muscles.


- Oversensitivity of bronchioles.


- Mild and moderate asthma:

- * infiltration of airways with lymphocytes and eosinophils
- * injury and loss of respiratory epithelium
- * degranulation of mastocytes
- * accumulation of collagen under basal membranes

- In advanced asthma:


- * occlusion of airways by mucus
- * hyperplasia/hypertrophy of smooth muscle cells
- * hyperplasia of epithelial cells





Eosinophils – asthma- glucocorticoides


- Eosinophils are one of the major cells in response to parasites of respiratory system
- They play a crucial role in pathogenesis of asthma and other allergic diseases. **In patients with asthma there are massive eosinophil infiltration in the airways.**
- **Treatment with corticosteroids** patients with asthma **decreases inflammation** in airways, mostly through **induction of eosinophil apoptosis**, then eosinophiles are phagocytosed by macrophages and epithelial cells.
- Some patients do not respond for treatment with corticosteroids. It can be associated with the presence of β splicing form of GR
- Eosinophils isolated from patients with asthma resistant to corticosteroid are also resistant to corticosterone-induced apoptosis.



Eosinophils – asthma- glucocorticoids


- In the case of massive apoptosis important is a fast phagocytosis of the dead cells. If not – the secondary necrosis can occur. The content of cells is released and induces inflammation.

- Major cells responsible for removal of apoptotic eosinophils are macrophages. **Glucocorticosteroids increase phagocytosis of eosinophils by macrophages and epithelial cells.**



phagocytosis of eosinophils by epithelial cell


- **Glucocorticoids are the basic drugs in treatment of asthma.**
- **Currently the major way of corticosteroid application is inhalation.**



Anabolic-androgenic steroids (AAS)

AAS are synthetic derivatives of testosterone originally designed to provide enhanced anabolic (tissue-building) potency with negligible androgenic (masculinizing) effects.

- Approximately, 60 different AAS are available that vary in their chemical structure and thus in their metabolic fate and physiological effects.



- Three main classes of AAS have been described:

I. Injectable compounds derived from esterification of the 17 β -hydroxyl group of testosterone (e.g. testosterone propionate, testosterone cypionate). Esterification retards degradation and prolongs the duration of action.


II. Injectable androgen esters called 19-nor-testosterone derivatives (e.g. nandrolone decanoate). The substitution at C19 extends the half-life.

III. Orally active compounds that are alkylated at C17 (e.g. 17 α -methyltestosterone, oxymetholone, methandrostenolone, and stanozolol).

Class I and II AAS **may be aromatized and act at the estrogen receptor**, whereas class III AAS are believed to have minimal estrogen receptor actions.

- AAS were originally developed for the treatment of hypogonadal dysfunction in men, initiation of delayed puberty, and growth promotion .
- They continue to be used today for these treatments, as well as for therapy in chronic conditions including HIV/AIDS, severe burns, anemia, etc.
- However, AAS administration is now predominantly one of abuse, and the medical benefits of low doses of AAS stand in sharp contrast to the potential health risks associated with the **excessive doses self-administered by athletes**. AAS are used, very often **in concentrations > 40 times higher than therapeutic doses**.
- At that time, more than one million adult Americans had or were using AAS to increase physical strength, endurance, athletic ability or muscle mass.
- Recent reports highlight the fact that the more insidious growth in the abuse of these drugs is not among elite athletes, but **among adolescent boys and girls**.
- Present estimations in the USA are the 4% of high school students have used AAS, and the greatest increase in AAS use over the past decade has been reported in adolescent girls.

- AAS increase aggressiveness both in men and women.
- AAS appear to modulate neural transmission both by classical AR-dependent changes in gene transcription and by nongenomic, allosteric modulation of specific receptors.
- ASS activate AR and possibly may increase its expression (some may possibly decrease the expression of PR or ER).
- **AAS change the expression of GABA_A receptor and allosterically modulate its activity,** as well as the expression of enzymes responsible for the synthesis of endogenous allosteric modulators.
- The GABA_A receptor provides the major mechanism for fast acting inhibition in the adult mammalian nervous system. It is the molecular targets of an extraordinarily diverse range of toxins and drugs that includes anxiolytic benzodiazepines, sedative barbiturates, anticonvulsants, convulsants (including a number of insecticides), general anesthetics, ethanol.



AAS in men

- AAS increases the level of liver enzymes in the blood (e.g. AST, ALT, AP, LDH)
- AAS decreases the synthesis of endogenous androgens, leading after longer treatment to hypogonadism (**atrophy of testes, decreased spermatogenesis**). These changes usually reverse after finishing the treatment.
- The second symptom is **growth of breasts** (because the level of estrogens is increased) and these changes can be irreversible.
- Libido is increased, but in the same time increased is also frequency of **erectile disorders**.



AAS in women

AAS leads to:

- disturbances of ovulation and menstrual cycle.
- **male-type baldness**,
- decreased voice,
- increased libido,
- development of hair pattern typical for men, male-pattern baldness
- development of **male-type musculature**.
- hypertrophy of clitoris

Treatment with androgens in pregnant women may lead to pseudohermaphroditism in children (girls) and fetal growth retardation.



Thank you and see you next week

What would be profitable to remember in June:

- Ligands for MR – why cortisol acts as mineralocorticoid only in some tissues
- Regulation of aldosterone synthesis – effect on hypertension
- Antiinflammatory activities of corticosteroids
- Differences between activity of $GR\alpha$ and $GR\beta$ – implications in therapy
- DAX1 and SF-1: general characteristics

Slides can be found in the library and at the Heme Oxygenase Fan Club page:

<https://biotka.mol.uj.edu.pl/~hemeoxygenase>

